Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Omid Hamid

Showing results (81-90 of 188) with videos related to

Pageof 19
Sort By:
Journal for Immunotherapy of Cancer|January 20, 2018
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trialHoward L Kaufman, Jeffery S Russell, Omid Hamid, et al.
Investigational New Drugs|August 7, 2019
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanomaShahneen Sandhu, Catriona M McNeil, Patricia LoRusso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2018
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)Tara C Mitchell, Omid Hamid, David C Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous MelanomaSylvia M Lee, Omid Hamid, Robert Jotte, et al.
The Lancet. Oncology|July 20, 2014
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b studyAntoni Ribas, Rene Gonzalez, Anna Pavlick, et al.
Journal of Translational Medicine|April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.
BMC Cancer|April 20, 2019
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid TumorsDavid S Hong, Patricia LoRusso, Omid Hamid, et al.
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
BMC Cancer|May 18, 2017
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Pageof 19

Showing results (81-90 of 188) with videos related to

Sort By:
Pageof 19
Journal for Immunotherapy of Cancer|January 20, 2018
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trialHoward L Kaufman, Jeffery S Russell, Omid Hamid, et al.
Investigational New Drugs|August 7, 2019
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanomaShahneen Sandhu, Catriona M McNeil, Patricia LoRusso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2018
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)Tara C Mitchell, Omid Hamid, David C Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous MelanomaSylvia M Lee, Omid Hamid, Robert Jotte, et al.
The Lancet. Oncology|July 20, 2014
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b studyAntoni Ribas, Rene Gonzalez, Anna Pavlick, et al.
Journal of Translational Medicine|April 18, 2023
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022Paolo A Ascierto, Christian Blank, Alexander M Eggermont, et al.
BMC Cancer|April 20, 2019
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid TumorsDavid S Hong, Patricia LoRusso, Omid Hamid, et al.
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
BMC Cancer|May 18, 2017
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Pageof 19